Letter to the Editor Regarding “Multiwavelength Photobiomodulation Improves Multiple Aspects of Visual Function in Early-Stage Dry Age-Related Macular Degeneration”

We read with interest the recent report by Kkerdnmez and Tedford evaluating multiwavelength photobiomodulation (PBM) in a real-world clinical setting for early-stage nonexudative age-related macular degeneration (AMD) [1].As one of the first non-randomized, single-center assessments of the LumiThera Valeda Light Delivery System (LumiThera, Inc., Poulsbo, WA, USA) outside a controlled trial, this study offers valuable insight into the translational potential of PBM.However, the modest visual acuity gains reported-particularly in the absence of a control or masking-may reflect test-retest variability or learning effects rather than true physiological improvement.A closer analysis of the methodology and results raises important questions regarding the clinical relevance and robustness of the findings.Below, we outline several key concerns.